Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanny Al-Samkari

Showing results (41-50 of 200) with videos related to

Pageof 20
Sort By:
American Journal of Hematology|April 1, 2018
Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulabilityHanny Al-Samkari, Jean M Connors
Seminars in Thrombosis and Hemostasis|December 13, 2019
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and TreatmentHanny Al-Samkari, David J Kuter
Cancers|August 17, 2018
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated ThrombosisHanny Al-Samkari, Jean M Connors
Hematology. American Society of Hematology. Education Program|December 7, 2019
Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancyHanny Al-Samkari, Jean M Connors
Cancer|February 20, 2020
How to focus our efforts in improving prognostic disclosure in oncologyHanny Al-Samkari, Arpan A Patel
Expert Review of Hematology|September 20, 2022
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiencyAndrew B Song, Hanny Al-Samkari
British Journal of Haematology|November 4, 2024
A second chance for avatrombopag in chemotherapy-induced thrombocytopeniaHanny Al-Samkari, Donald C Moore
British Journal of Haematology|September 22, 2023
Novel therapeutics and future directions for refractory immune thrombocytopeniaHanny Al-Samkari, Ellis J Neufeld
Annals of Translational Medicine|May 21, 2026
Mitapivat for sickle cell disease: the time is ripe for a new therapyAaron N Cheng, Hanny Al-Samkari
Platelets|September 2, 2022
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignanciesAbraham Z Cheloff, Hanny Al-Samkari
Pageof 20

Showing results (41-50 of 200) with videos related to

Sort By:
Pageof 20
American Journal of Hematology|April 1, 2018
Dual anticoagulation with fondaparinux and dabigatran for treatment of cancer-associated hypercoagulabilityHanny Al-Samkari, Jean M Connors
Seminars in Thrombosis and Hemostasis|December 13, 2019
Immune Thrombocytopenia in Adults: Modern Approaches to Diagnosis and TreatmentHanny Al-Samkari, David J Kuter
Cancers|August 17, 2018
The Role of Direct Oral Anticoagulants in Treatment of Cancer-Associated ThrombosisHanny Al-Samkari, Jean M Connors
Hematology. American Society of Hematology. Education Program|December 7, 2019
Managing the competing risks of thrombosis, bleeding, and anticoagulation in patients with malignancyHanny Al-Samkari, Jean M Connors
Cancer|February 20, 2020
How to focus our efforts in improving prognostic disclosure in oncologyHanny Al-Samkari, Arpan A Patel
Expert Review of Hematology|September 20, 2022
An evaluation of mitapivat for the treatment of hemolytic anemia in adults with pyruvate kinase deficiencyAndrew B Song, Hanny Al-Samkari
British Journal of Haematology|November 4, 2024
A second chance for avatrombopag in chemotherapy-induced thrombocytopeniaHanny Al-Samkari, Donald C Moore
British Journal of Haematology|September 22, 2023
Novel therapeutics and future directions for refractory immune thrombocytopeniaHanny Al-Samkari, Ellis J Neufeld
Annals of Translational Medicine|May 21, 2026
Mitapivat for sickle cell disease: the time is ripe for a new therapyAaron N Cheng, Hanny Al-Samkari
Platelets|September 2, 2022
Romiplostim for PARP inhibitor-induced thrombocytopenia in solid tumor malignanciesAbraham Z Cheloff, Hanny Al-Samkari
Pageof 20